newsEU approves Koselugo for treatment of neurofibromatosis and plexiform neurofibromas22 June 2021 | By Hannah Balfour (European Pharmaceutical Review)The European approval of Koselugo was based on its ability to reduce inoperable plexiform neurofibromas in paediatric patients with neurofibromatosis type 1.
newsHighlights of the EMA’s human medicine committee meeting, April 202126 April 2021 | By Hannah Balfour (European Pharmaceutical Review)The Committee for Medicinal Products for Human Use (CHMP) recommended eight drugs for approval and nine indication extensions.